Figure 1From: The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrelFrequency distribution (in deciles) of VASP-PRI (Panel a) and VerifyNow-PRU (Panel b) in patients on clopidogrel as single antiplatelet therapy. Cut-off levels ≥55 and ≥170, respectively, as indicated.Back to article page